Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $7.86 Average Target Price from Brokerages

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $7.8571.

A number of brokerages have issued reports on GANX. Roth Capital decreased their price objective on Gain Therapeutics from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. BTIG Research restated a “buy” rating and issued a $9.00 price target on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Maxim Group boosted their price objective on shares of Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, October 13th.

Institutional Investors Weigh In On Gain Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Gain Therapeutics during the 3rd quarter worth approximately $28,000. JPMorgan Chase & Co. bought a new stake in shares of Gain Therapeutics during the third quarter worth $47,000. Benedict Financial Advisors Inc. boosted its stake in shares of Gain Therapeutics by 55.6% during the third quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock valued at $62,000 after purchasing an additional 12,500 shares during the period. Squarepoint Ops LLC bought a new position in shares of Gain Therapeutics in the third quarter worth about $68,000. Finally, Kovitz Investment Group Partners LLC purchased a new position in Gain Therapeutics in the 1st quarter worth about $91,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Price Performance

GANX stock opened at $2.83 on Thursday. Gain Therapeutics has a 52 week low of $1.41 and a 52 week high of $3.06. The firm has a market capitalization of $102.56 million, a P/E ratio of -4.64 and a beta of 0.13. The company has a fifty day simple moving average of $1.94 and a two-hundred day simple moving average of $1.83. The company has a quick ratio of 1.79, a current ratio of 2.52 and a debt-to-equity ratio of 0.05.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.15). Analysts anticipate that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.